Nature Communications (May 2020)
PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma
- Xian-De Liu,
- Wen Kong,
- Christine B. Peterson,
- Daniel J. McGrail,
- Anh Hoang,
- Xuesong Zhang,
- Truong Lam,
- Patrick G. Pilie,
- Haifeng Zhu,
- Kathryn E. Beckermann,
- Scott M. Haake,
- Sevinj Isgandrova,
- Margarita Martinez-Moczygemba,
- Nidhi Sahni,
- Nizar M. Tannir,
- Shiaw-Yih Lin,
- W. Kimryn Rathmell,
- Eric Jonasch
Affiliations
- Xian-De Liu
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- Wen Kong
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- Christine B. Peterson
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center
- Daniel J. McGrail
- Department of Systems Biology, The University of Texas MD Anderson Cancer Center
- Anh Hoang
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- Xuesong Zhang
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- Truong Lam
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- Patrick G. Pilie
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- Haifeng Zhu
- Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center
- Kathryn E. Beckermann
- Division of Hematology and Oncology, Vanderbilt University Medical Center
- Scott M. Haake
- Division of Hematology and Oncology, Vanderbilt University Medical Center
- Sevinj Isgandrova
- Institute of Biosciences and Technology, Texas A&M Health Science Center
- Margarita Martinez-Moczygemba
- Institute of Biosciences and Technology, Texas A&M Health Science Center
- Nidhi Sahni
- Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center
- Nizar M. Tannir
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- Shiaw-Yih Lin
- Department of Systems Biology, The University of Texas MD Anderson Cancer Center
- W. Kimryn Rathmell
- Vanderbilt-Ingram Cancer Center, Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center
- Eric Jonasch
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- DOI
- https://doi.org/10.1038/s41467-020-15959-6
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 14
Abstract
PBRM1, encoding for a subunit of the SWI/SNF complex, is the second most frequently mutated gene in clear cell renal cell carcinoma (ccRCC). Here, the authors show that PBRM1 loss reduces IFNγ-mediated signalling resulting in a less immunogenic tumor microenvironment and that PBRM1 mutations correlate with lack of response to checkpoint inhibitor therapy in ccRCC patients..
